Skip to main content

Advertisement

Table 2 Treatment administered to the subset of patients enrolled in the ChemoFx (Precision Therapeutics, Inc., Pittsburgh, PA) Physician Reported Outcomes Study between assays

From: In vitro chemoresponse in metachronous pairs of gyneclologic cancers

  N = 36
Bevacizumab/Carboplatin/Paclitaxel 2 (6%)
Carboplatin/Cisplatin/Paclitaxel 7 (19%)
Carboplatin/Gemcitabine/Paclitaxel 1 (3%)
Carboplatin/Docetaxel 2 (6%)
Carboplatin/Paclitaxel 22 (61%)
Cisplatin/Docetaxel/Paclitaxel 1 (3%)
Cisplatin/Paclitaxel 1 (3%)